Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Pinilla Alba on Safety Findings of the PARTNER Trial in Breast Cancer

December 13th 2019

Karen Pinilla Alba, MD, discusses the safety findings stages 1 and 2 of the phase II/III PARTNER trial in triple negative and/or germline BRCA-mutated breast cancer.

Neoadjuvant Durvalumab Regimen Shows Promise in TNBC

December 13th 2019

A durvalumab-based neoadjuvant regimen induced an impressive pathologic complete response rate in patients with triple-negative breast cancer.

Dr. Conte on the OlympiAD Trial in BRCA-Mutated HER2-Negative Breast Cancer

December 13th 2019

Pierfranco Conte, MD, discusses the findings of the OlympiAD trial in BRCA-mutated HER2-negative metastatic breast cancer.

Accelerated Partial Breast Irradiation Could Replace Whole Breast Irradiation in Low-Risk Early Breast Cancer

December 13th 2019

Accelerated partial breast irradiation using intensity-modulated radiotherapy is not significantly different from whole breast irradiation in preventing recurrence in patients with low-risk early breast cancer.

Extended Follow-Up Shows Continued Olaparib Benefit in BRCA+ MBC

December 13th 2019

Olaparib continued to show a numerical overall survival (OS) benefit with a favorable hazard ratio for OS versus chemotherapy in patients with BRCA-positive, HER2-negative metastatic breast cancer, according to an extended, exploratory follow-up analysis of the phase III OlympiAD trial.

Neoadjuvant Atezolizumab Regimen Slightly Improves pCR in TNBC

December 13th 2019

Atezolizumab (Tecentriq) in combination with carboplatin and nab-paclitaxel (Abraxane) did not lead to a statistically significant increase in pathologic complete response (pCR) rate compared with carboplatin/nab-paclitaxel alone in patients with early high-risk and locally advanced triple-negative breast cancer,

Survival Benefit Hinted at With Durvalumab Maintenance in TNBC

December 13th 2019

Maintenance durvalumab may improve outcomes versus chemotherapy in patients with triple-negative breast cancer or those with PD-L1–positive breast cancer across several subtypes, according to exploratory analyses from the phase II randomized SAFIR02-IMMUNO trial presented at the 2019 San Antonio Breast Cancer Symposium.

Anastrozole Maintains Breast Cancer Prevention Effect in Long-Term Follow-Up

December 12th 2019

The aromatase inhibitor anastrozole maintained a preventive effect for postmenopausal women at high risk for breast cancer nearly 12 years after discontinuing treatment.

Benefit in pCR Rates Are Achieved With Pembrolizumab in Early TNBC

December 12th 2019

Patients with triple-negative breast cancer have greater rates of pathologic complete responses when pembrolizumab is added to neoadjuvant and adjuvant chemotherapy. Furthermore, these benefits are observed across patient subgroups, most notably in those patients with stage III and/or node-positive disease.

Palbociclib Real-World Results Indicate OS Benefit in Frontline HR+/HER2- Breast Cancer

December 12th 2019

Real-world data for frontline palbociclib indicate that the positive progression-free survival data observed with the CDK4/6 inhibitor in the pivotal PALOMA-2 trial would likely translate to an overall survival benefit in patients with HR-positive/HER2-negative metastatic breast cancer

Dr. Hurvitz on Using ADCs in HER2+ Breast Cancer

December 12th 2019

Sara A. Hurvitz, MD, associate professor of medicine and medical oncologist, University of California Los Angeles, discusses the use of antibody-drug conjugates in HER2-positive breast cancer.

S-1 Improves iDFS in HR+, HER2- Breast Cancer

December 12th 2019

Adding the novel oral fluoropyrimidine derivative S-1 to adjuvant endocrine therapy significantly improved invasive disease-free survival for Japanese patients with HR-positive, HER2-negative breast cancer.

FDA Approves Generic Everolimus Tablets

December 11th 2019

The FDA has approved 2 abbreviated new drug applications for everolimus (Afinitor) tablets for the treatment of patients with select malignancies.

Precision Medicine Propels Research Efforts in Breast Cancer

December 5th 2019

Mark E. Robson, MD, provides a snapshot of the precision focus in breast cancer, as well as the emergence of biosimilars in the field.

Sacituzumab Govitecan TNBC Application Resubmitted to FDA

December 4th 2019

Immunomedics has resubmitted its biologics license application to the FDA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received ≥2 prior therapies for metastatic disease.

NICE Approves Palbociclib Combo for HR+ Advanced Breast Cancer

December 3rd 2019

The UK National Institute for Health and Care Excellence has approved palbociclib in combination with fulvestrant for the treatment of female patients with hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.

Genomic Era Trials Drive Discovery

December 2nd 2019

Innovative clinical trials designed to exploit the explosion of data on the drivers of cancer are demonstrating value as tools to explore potential signals of efficacy across tumor types, according to oncology experts. These studies have become a feature of the drug discovery landscape in oncology and are likely to remain part of the fabric of clinical research in the genomic era.

West Cancer Center Faculty Walk Through Ongoing Breast Cancer Research Efforts

November 27th 2019

Experts from West Cancer Center highlighted the exciting research being conducted at their institution.

Transformative Treatments Take Hold Across Breast Cancer Settings

November 26th 2019

Lee S. Schwartzberg, MD, FACP, discusses paradigm shifts in hormone receptor–positive breast cancer and triple-negative breast cancer.

Reviewing Breakthroughs in Breast Cancer in Raleigh

November 20th 2019

We traveled to Raleigh, North Carolina, for a State of the Science Summit™ on Breast Cancer, which featured insights from the Duke Cancer Institute faculty.